The use CGRP-related monoclonal antibodies and lasmiditan for migraine management in children and adolescents

Abstract

　 A retrospective analysis of 87 adolescent patients aged 13 to 17 years with migraine who attended a headache clinic demonstrated that the majority exhibited high frequency and severity of migraine attacks. Additionally, a subset of patients presented with comorbid orthostatic dysregulation and/or psychiatric disorders. In the management of migraine in adolescents, early initiation of prophylactic pharmacotherapy should be considered when non-pharmacological interventions and acute treatments prove insufficient and when the condition significantly interferes with daily functioning. Although clinical trials investigating the efficacy and safety of calcitonin gene-related peptide (CGRP) -related monoclonal antibodies in individuals under 18 years of age are currently lacking, their use may be justified in patients aged 15 to 17 years who experience substantial disability due to the limited effectiveness of conventional preventive therapies.